RxDoctor Payments Data

Zaifi Shanavas, MD

Gastroenterology · Silver Spring, MDNPI 1518054519

Payments from drug & device makers

$8,800in general payments, 2019–2025

Across 338 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Bristol Myers Squibb$758
  • Takeda Pharmaceuticals U.S.A., Inc.$482
  • E.r. Squibb & Sons, L.L.C.$471
  • Pfizer$364
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$8,72599%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,800 in reported general payments places this provider in the 70th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$221,490
Medicare patients
464
Services billed
5,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexlansoprazole DrDexlansoprazole27$8,314
ClenpiqSod Picosulf/Mag Ox/Citric Ac37$6,343
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates96$5,463
Mesalamine15$5,455
Pantoprazole Sodium184$3,041
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,063
Famotidine44$757
Esomeprazole Magnesium26$620
Budesonide DrBudesonide12$592
Omeprazole40$508
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl13$187
Sucralfate11$183
Prednisone12$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$51$6,34337 claims
Braintree Laboratories, Inc.Sutab$114$2,06313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →